A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, 2-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-8236 by Inhalation of Single Ascending Doses in Healthy Subjects and Multiple Ascending Doses in Subjects With Stable, Mild Asthma
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2018
At a glance
- Drugs TD 8236 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors Theravance Biopharma
- 27 Nov 2018 According to Theravance Biopharma media release, First Subject Dosed in this study.
- 20 Nov 2018 Status changed from not yet recruiting to recruiting.
- 27 Aug 2018 Status changed from planning to not yet recruiting.